21. Neželeni učinki sistemskega zdravljenja rakaErik Škof, 2022, published scientific conference contribution Abstract: Pri beleženju neželenih učinkov sistemskega zdravljenja uporabljamo mednarodne kriterije “Common Terminology Criteria for Adverse Events”, ki jih je ustanovil Ameriški Nacionalni inštitut za zdravljenje raka. V prispevku prikazujemo definicije izrazov, ki jih uporabljamo pri opisovanju in vrednotenju neželenih učinkov zdravljenja. Po Zakonu o zdravilih in Pravilniku o farmakovigilanci zdravil za uporabo v humani medicini je poročanje o domnevnih neželenih učinkih za zdravstvene delavce obvezno. Prikazujemo osnovna navodila in informacije za prijavo neželenih učinkov zdravljenja. Keywords: neželeni učinki, bolniki, sistemsko zdravljenje Published in DiRROS: 17.01.2023; Views: 428; Downloads: 108 Full text (69,50 KB) |
22. Sodobno zdravljenje lokalno napredovalega in recidivnega raka dankeErik Brecelj, 2022, published scientific conference contribution Abstract: Zdravljenje lokalno napredovalega in recidivnega raka danke je zahtevno. Z uvedbo boljše diagnostike, novih načinov predoperativnega zdravljenja na eni strani in z bolj agresivno kirurško terapijo na drugi strani dosegamo več R0 resekcij, ki edine omogočajo potencialno ozdravitev. Še vedno pa so ti posegi za bolnike neredko mutilantni. Z ustreznimi tehnikami rekonstrukcije dosegamo večjo možnost resektabilnosti, hkrati pa so posledice kirurškega zdravljenja manjše. Pomembna pri vrnitvi bolnika v normalno življenje sta prehranska podpora in rehabilitacija. Tako kompleksno zdravljenje je možno samo v multidisciplinarnem timu. Keywords: rak danke, kirurško zdravljenje, rak prebavil Published in DiRROS: 13.01.2023; Views: 579; Downloads: 106 Full text (88,46 KB) |
23. |
24. Smernice za obravnavo bolnikov s skvamoznoceličnim karcinomom analnega kanala in kože perinealno (analnega roba)Franc Anderluh, Irena Oblak, Ajra Šečerov Ermenc, Ana Jeromen, Erik Brecelj, Martina Reberšek, Vaneja Velenik, 2022, professional article Keywords: rak analnega kanala, rak analnega roba, radiokemoterapija, obsevanje Published in DiRROS: 15.12.2022; Views: 532; Downloads: 116 Full text (134,47 KB) |
25. Smernice za zdravljenje bolnikov z rakom požiralnika in ezofagogastričnega stika (EGS)Franc Anderluh, Marko Boc, Goran Gačevski, Gorana Gašljević, Samo Horvat, Nežka Hribernik, Marija Ignjatović, Ana Jeromen, Jera Jeruc, Peter Korošec, Tanja Mesti, Srdjan Novaković, Irena Oblak, Janja Ocvirk, Martina Reberšek, Nada Rotovnik-Kozjek, Matevž Srpčič, Ajra Šečerov Ermenc, Borut Štabuc, Vaneja Velenik, Neva Volk, Vesna Zadnik, 2022, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: rak požiralnika, rak ezofagogastritičnega stika, smernice, zdravljenje Published in DiRROS: 07.09.2022; Views: 720; Downloads: 272 Full text (3,50 MB) This document has many files! More... |
26. Real-world data on detection of germline and somatic pathogenic/likely pathogenic variants in BRCA1/2 and other susceptibility genes in ovarian cancer patients using next generation sequencingVida Stegel, Ana Blatnik, Erik Škof, Vita Šetrajčič Dragoš, Mateja Krajc, Brigita Gregorčič, Petra Škerl, Ksenija Strojnik, Gašper Klančar, Marta Banjac, Janez Žgajnar, Maja Ravnik-Oblak, Srdjan Novaković, 2022, original scientific article Abstract: Detection of germline and somatic pathogenic/likely pathogenic variants (PV/LPV) in BRCA genes is at the moment a prerequisite for use of PARP inhibitors in different treatment settings of different tumors. The aim of our study was to determine the most appropriate testing workflow in epithelial ovarian cancer (EOC) patients using germline and tumor genotyping of BRCA and other hereditary breast and/or ovarian cancer (HBOC) susceptibility genes. Consecutive patients with advanced non-mucinous EOC, who responded to platinum-based chemotherapy, were included in the study. DNA extracted from blood and FFPE tumor tissue were genotyped using NGS panels TruSightCancer/Hereditary and TruSight Tumor 170. Among 170 EOC patients, 21.8% had BRCA germline or somatic PV/LPV, and additionally 6.4% had PV/LPV in other HBOC genes. Sensitivity of tumor genotyping for detection of germline PV/LPV was 96.2% for BRCA genes and 93.3% for HBOC genes. With germline genotyping-only strategy, 58.8% of HBOC PV/LPV and 68.4% of BRCA PV/LPV were detected. By tumor genotyping-only strategy, 96.1% of HBOC PV/LPV and 97.4% of BRCA PV/LPV were detected. Genotyping of tumor first, followed by germline genotyping seems to be a reasonable approach for detection of PV/LPV in breast and/or ovarian cancer susceptibility genes in non-mucinous EOC patients. Keywords: BRCA, ovarian cancer, tumor genotyping, HBOC Published in DiRROS: 06.09.2022; Views: 536; Downloads: 284 Full text (2,35 MB) This document has many files! More... |
27. Priročnik za bolnike z izločalno stomoAndreja Klinc, Dragica Tomc, Sabina Medjedović, 2021, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: rak črevesja, rak sečil, stoma Published in DiRROS: 14.07.2022; Views: 627; Downloads: 196 Full text (769,40 KB) |
28. Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccinationUrška Janžič, Urška Bidovec, Katja Mohorčič, Loredana Mrak, Nina Fokter Dovnik, Marija Ivanović, Maja Ravnik, Marina Čakš, Erik Škof, Jerneja Debeljak, Peter Korošec, Matija Rijavec, 2022, original scientific article Abstract: Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted. Keywords: onkološko zdravljenje, imunogenost, osnovno cepljenje mRNA, čvrsti tumorji, anticancer treatment, immunogenicity, mRNA-based vaccination, solid cancer Published in DiRROS: 24.06.2022; Views: 822; Downloads: 337 Full text (2,03 MB) |
29. Design and degradation of permanently porous vitamin C and zinc-based metal-organic frameworkTia Kristian Tajnšek, Erik Svensson Grape, Tom Willhammar, Tatjana Antonić Jelić, Uroš Javornik, Goran Dražić, Nataša Zabukovec Logar, Matjaž Mazaj, 2022, original scientific article Published in DiRROS: 31.03.2022; Views: 729; Downloads: 449 Full text (1,43 MB) This document has many files! More... |
30. Smernice za obravnavo bolnikov s skvamoznoceličnim karcinomom analnega kanala in kože perinealno (analnega roba)2020, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: rak analnega kanala, rak analnega roba, bolniki, zdravljenje Published in DiRROS: 18.03.2022; Views: 705; Downloads: 382 Full text (407,06 KB) This document has many files! More... |